Clinical Trials Logo

Carcinosarcoma clinical trials

View clinical trials related to Carcinosarcoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04906382 Terminated - Lynch Syndrome Clinical Trials

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient tumors (dMMR) may have difficulty repairing DNA mutations during replication that may affect tumor's response to therapy. Immunotherapy with monoclonal antibodies, such as tislelizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tislelizumab may help treat patients with mismatch repair deficient endometrial cancer.

NCT ID: NCT04688749 Terminated - Melanoma (Skin) Clinical Trials

Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage

DermaSense
Start date: July 17, 2019
Phase:
Study type: Observational

The purpose of this clinical study is to evaluate if the DermaSense prototype EIS scanner can provide medical decision support which can complement dermoscopy-based identification of the disease at time of biopsy decision.

NCT ID: NCT03924245 Terminated - Clinical trials for Fallopian Tube Cancer

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Start date: October 1, 2020
Phase: Phase 1
Study type: Interventional

This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Olaparib and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03641287 Terminated - Ovarian Cancer Clinical Trials

The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

Start date: December 5, 2018
Phase: N/A
Study type: Interventional

Many individuals with ovarian cancer experience distress, fatigue, weakness, anxiety, and other symptoms that decrease quality of life. Moderate exercise may improve quality of life, decrease distress, and improve biomarkers associated with prognosis in individuals with ovarian cancer. This clinical trial studies how well moderate exercise works in improving distress, quality of life, and biomarkers of angiogenesis and chronic stress in individuals with ovarian, fallopian tube, and primary peritoneal cancer.

NCT ID: NCT03509207 Terminated - Leiomyosarcoma Clinical Trials

Vorinostat (SAHA) in Uterine Sarcoma

Start date: December 14, 2017
Phase: Phase 2
Study type: Interventional

Uterine sarcomas are rare tumors with a poor prognosis. The main purpose of this phase II proof-of-principle- pilot study is to test the efficacy of the hydroxamic acid-based Histone deacetylase inhibitor (HDACI) Vorinostat (SAHA) as monotherapy in patients with HDAC-positive, progressive, metastatic uterine sarcomas and mixed epithelial and mesenchymal tumors after prior anti-proliferative therapy.

NCT ID: NCT01367301 Terminated - Clinical trials for Uterine Carcinosarcoma

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

Start date: July 8, 2011
Phase: N/A
Study type: Interventional

This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving radiation with chemotherapy may kill more tumor cells.

NCT ID: NCT01061606 Terminated - Clinical trials for Uterine Carcinosarcoma

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Start date: January 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well temsirolimus works in treating patients with recurrent or persistent cancer of the uterus. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.